Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) is frequently in the news for developments related to its stabilized hypochlorous acid (HOCl) products based on patented Microcyn technology. The company issues regular updates on product launches, regulatory milestones, distribution partnerships, and financial results, giving investors and industry observers insight into how its HOCl portfolio is being deployed in wound care, eye care, oral and nasal care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants.
News coverage often highlights Sonoma’s expansion into consumer and professional markets. Recent press releases describe HOCl-based diaper rash products for infants and children launched into large U.S. retailers, hypochlorous acid-based acne products placed in retail pharmacy chains in the United Kingdom, and a Microcyn-based facial spray listed under the FDA’s Modernization of Cosmetics Regulation Act of 2022 (MoCRA). The company also reports on collaborations such as its HOCl wound cleanser manufactured for Medline Industries, LP for distribution into U.S. hospital systems and home healthcare channels.
Regulatory and recognition updates are another key theme. Sonoma has announced successful transition of its European products to the EU Medical Device Regulation (MDR), registrations with the MHRA in the United Kingdom, and multiple seals for Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel from organizations such as the National Psoriasis Foundation and the National Rosacea Society. Financial news includes quarterly and annual results, revenue trends by region, and non-GAAP metrics such as EBITDA loss.
By following the SNOA news feed, readers can monitor how Sonoma’s HOCl-based products are progressing through new markets, how its regulatory footprint is evolving, and how these developments are reflected in reported financial performance and corporate actions.
Sonoma Pharmaceuticals (Nasdaq: SNOA) reported a 12% revenue increase to $4.94 million for Q3 FY2020, driven by sales growth in Latin America and Europe, despite a decline in U.S. revenue due to COVID-19. Operating expenses decreased by 31% to $2.13 million, primarily from headcount reductions and facility closures. The net loss from continuing operations improved to $626,000 compared to $1.21 million in Q3 FY2019. Over nine months, revenue rose 21% to $16.47 million, although gross margins decreased to 41%. Sonoma's cash reserves increased to $5.44 million, signifying improved liquidity.
Sonoma Pharmaceuticals (Nasdaq: SNOA) announces that its Dermodacyn® disinfectant has received import clearance as a medical device for Thailand. This product, which has shown effectiveness against SARS-CoV-2, is now available in pharmacies and online in Hong Kong and Thailand. Dermodacyn is designed for disinfecting areas that may harbor harmful bacteria and viruses, with safety for human use being a key feature. Sonoma's CEO stated plans for ongoing research and development to expand product offerings.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference from January 11-14, 2021. The presentation will be available on-demand starting at 6:00 AM ET on January 11. Registration for the presentation can be accessed here. The company specializes in stabilized hypochlorous acid products for various healthcare applications.
Sonoma Pharmaceuticals (Nasdaq: SNOA) has entered into a non-exclusive distribution agreement with Gabriel Science, LLC to market its Microcyn® Technology products in the dental sector, receiving its first order.
Endocyn®, a product in this line, is a biocompatible root canal irrigant shown to have lower cellular toxicity than traditional irrigants in a study by Louisiana State University. The partnership aims to enhance Sonoma's market presence in dental healthcare, promoting advanced treatment options for dental conditions.